Evaluation of the WIDER I system for antimicrobial susceptibility testing of clinical isolates of Haemophilus influenzae and Streptococcus pneumoniae

Clin Microbiol Infect. 2003 May;9(5):449-52. doi: 10.1046/j.1469-0691.2003.00580.x.

Abstract

The aim of this study was to evaluate the WIDER I system for susceptibility testing of Haemophilus influenzae and Streptococcus pneumoniae. MICs of 12 antimicrobials against 42 H. influenzae and 58 S. pneumoniae strains were determined using 1W MIC panels and compared with those obtained by microdilution. Overall essential agreements were >99%. Very major errors were not detected. Major errors occurred with ampicillin (1.7% H. influenzae). Minor errors were 2.3% (amoxicillin-clavulanate, cefuroxime, chloramphenicol), 7.1% (ampicillin) and 16.7% (clarithromycin) for H. influenzae, and 1.7% (chloramphenicol, erythromycin, meropenem), 3.4% (amoxicillin-clavulanate, cefuroxime, tetracycline) and 8.6% (levofloxacin) for S. pneumoniae. The WIDER I system is a reliable method for susceptibility testing of H. influenzae and S. pneumoniae.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Bacterial Infections / prevention & control
  • Bacterial Typing Techniques
  • Haemophilus influenzae / drug effects*
  • Haemophilus influenzae / isolation & purification
  • Humans
  • Image Processing, Computer-Assisted*
  • Microbial Sensitivity Tests / instrumentation*
  • Reference Standards
  • Streptococcus pneumoniae / drug effects*
  • Streptococcus pneumoniae / isolation & purification

Substances

  • Anti-Bacterial Agents